adenomyosis, endometriosis
Conditions
Interventions
1:Gestrinone, 2.5 mg, twice per week, last for 3 months
2:Gestrinone, 2.5 mg, 3 times a week, last for 1 months
then 2.5 mg, twice per week, last for 2 months
3:Gestrinone, 2.5 mg, 3 times a week, last for 3months. It can accompany use Liver protect drug such as Bifendate.
Sponsors
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Sexual life history, 18-45 years of age in premenopausal women; 2. The patients with endometriosis or adenomyosis are diagnosed by clinical or pathological diagnosis standards;Clinical diagnosis standards of pelvic endometriosis: (1) pain(dysmenorrhea, chronic pelvic pain, intercourse pain), infertility; (2) gynecological examination and auxiliary examination: lesions of endometriosis examined by pelvic examination, lesions of endometriosis examined by imaging examination, the level of CA125 increased slightly or moderately; (3) laparoscopy: Laparoscopy is the general method of diagnosis of endometriosis, diagnosis is based on the morphology of lesions, and not all of the lesions can be confirmed by pathological diagnosis. Clinical diagnosis standards of adenomyosis: (1) symptoms (dysmenorrhea, menses increased, infertility), gynecological examination(uterus enlarged, texture coarse); (2) ultrasonography (uterus enlarged,myometrial thickness increased, posterior wall of uterus thickened obviously, endometrium moved forward, equal or strong echo lesions with spotty low echo, lesions with unclear boundary); (3) MRI: lesions with unclear boundary and lower signal intensity, high signal intensity on T2, EMI>12mm; (4) high level of CA125; (5) diagnosised by pathology. The Second is the essential indicator for diagnosis, and with the other one or more standards to can make a clinical diagnosis; 3. Agree to take part in the trial and in accordance with the provisions of the follow-up.
Exclusion criteria
Exclusion criteria: (1) pregnant and lactating women; (2) patients with bilateral oophorectomy; (3) Gestrinone or the reagent containing excipients allergy; (4) Having a history of the metabolic or vascular disease caused by estrogen or progesterone treatment; (5) Suffering from liver disease(AST>60U/ml,ALT>60U/ml); (6) used hormone therapy in last 3 monthes; (7) Suffering from thrombotic disease, coagulation disorders; (8) patients with IUD; (9) patients with dysfunctional uterine bleeding, endometrial sarcomatoid variant, uterine polyps, submucous myoma of uterus cervical polyps; (10) not sign the informed consent; (11) poor compliance, nor follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vaginal bleeding mode and time; | — |
Countries
China
Contacts
Public ContactDuan Hua
Outcome results
None listed